Treatment of lentigo maligna with topical imiquimod

British Journal of Dermatology, Supplement

Volumn 149, Issue 66, 2003, Pages 66-69

  Naylor, M F ^b   Crowson, N ^a   Kuwahara, R ^b   Teague, K ^c   Garcia, C ^b   Mackinnis, C ^b   Haque, R ^b   Odom, C ^d   Jankey, C ^b   Cornelison, R L ^b  

^a St John's Hospital   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c OKLAHOMA STATE UNIVERSITY   (United States)

^d NONE

Author keywords

Imiquimod; Lentigo maligna; Stage 0 melanoma; Topical therapy

Indexed keywords

ANTIBIOTIC AGENT; IMIQUIMOD;

ADULT; AGED; CANCER RECURRENCE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; ERYTHEMA; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; MALAISE; MALE; MALIGNANT LENTIGO; PATIENT REFERRAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN BIOPSY; SKIN EDEMA; SKIN IRRITATION; SKIN ULCER; SUPERINFECTION; TREATMENT FAILURE; TREATMENT WITHDRAWAL; TUMOR BIOPSY;

EID: 9144253900     PISSN: 0366077X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0366-077x.2003.05637.x     Document Type: Conference Paper

References (4)

1. Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol 2000; 143: 843-5.
2. Cox NH, Aitchison TC et al. Comparison between lentigo maligna melanoma and other histogenetic types of malignant melanoma of the head and neck. Br J Cancer 1996; 73: 940-4.
3. Hemmi H, Kaisho T, Takeuchi O, Sato S et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nature Immunol 2002; 3: 196-200.
4. Agarwal-Antal N, Bowen GM et al. Histologic evaluation of lentigo maligna with permanent sections: implications regarding current guidelines. J Am Acad Dermatol 2002; 47: 743-8.